Avatrombopag

From WikiProjectMed
Jump to navigation Jump to search

Avatrombopag
Avatrombopag.svg
Names
Pronunciationa" va trom' boe pag
Trade namesDoptelet
Other namesAvatrombopag maleate
  • 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
Clinical data
Drug classThrombopoietin receptor agonist[1]
Main usesLow platelets in chronic liver disease[2][3]
Side effectsFever, abdominal pain, nausea, headache, tiredness, peripheral swelling[2]
Pregnancy
category
  • US: N (Not classified yet)
Routes of
use		By mouth
Typical dose40 to 60 mg OD[3]
External links
AHFS/Drugs.comMonograph
MedlinePlusa618032
Legal
License data
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Chemical and physical data
FormulaC29H34Cl2N6O3S2
Molar mass649.65 g·mol−1
3D model (JSmol)
  • C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
  • InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) checkY
  • Key:OFZJKCQENFPZBH-UHFFFAOYSA-N

Avatrombopag, sold under the brand name Doptelet, is a medication used to treat low platelets in chronic liver disease when an invasive medical procedure is required.[2][3] It is taken by mouth.[1]

Common side effects include fever, abdominal pain, nausea, headache, tiredness, and peripheral swelling.[2] Other side effects may include blood clots.[2] Use in pregnancy may harm the baby.[2] Safety in pregnancy or breastfeeding is unclear.[1] It is a thrombopoietin receptor agonist, which increases platelet production.[1]

Avatrombopag was approved for medical use in the United States in 2018 and Europe in 2019.[2][3] In the United Kingdom a course of treatment costs the NHS £640 to £960 as of 2020.[4] In the United States this amount is 3,650 USD to 5,500 USD.[5]

Medical uses

Dosage

It should be started 10 days before the procedure.[3] It is used at a dose of 40 to 60 mg per day, depending on a persons platelets, for 5 days.[2]

References

  1. ↑ 1.0 1.1 1.2 1.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1079. ISBN 978-0857114105.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Avatrombopag Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 16 January 2022.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 22 May 2020. Retrieved 2 May 2020.
  4. ↑ "Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure". Archived from the original on 17 January 2022. Retrieved 16 January 2022.
  5. ↑ "Doptelet Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 16 January 2022.

External links

External sites:
Identifiers:
Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Avatrombopag&oldid=1375840"